A fund with sector focus

Rhenman Healthcare Equity L/S is a long biased hedge fund based on a fundamental approach. The fund invests in global healthcare equities. Our expertise and our unique working method, where the portfolio managers are supported by the Scientific Advisory Board and their global networks, have enabled the fund to reach a high absolute level of returns since its inception in 2009.

Rhenman Healthcare Equity L/S (RHE L/S)

Rhenman Healthcare Equity L/S (RHE L/S)
April 2026
The fund performance is calculated and reported once a month.
FUND CLASSNAVDEVELOPMENT 1 MONTHTHIS YEARSINCE FUND STARTSTART DATE
IC1 (EUR)853.09-0.52%-12.70%753.09%2009-06-22
IC3 (EUR)1110.92-0.46%-12.48%1010.92%2009-07-31
IC2 (SEK)676.17-1.64%-12.30%576.17%2012-12-31
ID1 (SEK)
Distributing
352.15-1.69%-16.17%252.15%2012-04-30
IC1 (USD)225.961.24%-12.81%125.96%2015-01-31
RC1 (EUR)720.80-0.57%-12.85%620.80%2010-08-31
RC1 (SEK)767.71-1.73%-12.60%667.71%2009-06-22
RC2 (SEK)826.52-1.69%-12.45%726.52%2009-06-22

Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.

Objective
The fund aims to generate an average annual net return of at least 12 percent over time, regardless of the global stock market’s performance.
Specialized portfolio managers in a complex sector

Our investment team consists of portfolio managers who are responsible for different parts of the sector. The sub-sectors, pharmaceuticals, biotech, medical technology and healthcare services, all have different characteristics and drivers. The high level of innovation and complexity in the sector requires in-depth analysis.

Dynamic portfolio construction

Our portfolio construction is an important component in our model to reach a level of balance between risk and return in the fund. Our diversified portfolio consists of around 100-140 stocks, where several individual investments are less than 1 percent of the total portfolio. This method enables us to pressure-test newer, high potential companies early on in their journey and allow the position to grow gradually within the portfolio. Companies can also be removed without any major impact on the portfolio as a whole.

The fund has a global investment universe. The majority of the positions are, however, in the US where most of the healthcare industry is based.

”At Rhenman & Partners we combine scientific, stock market and regulatory expertise to create an edge in healthcare fund management”
Hugo Schmidt
Portfolio Manager

Retail share class information 

SHARE CLASSCURRENCYMINIMUM INVESTMENTANNUAL MANAGEMENT + PERF. FEEISIN
RC1SEK5002.0% + 20% performance feeLU0417597712
RC2SEK2 500 0001.5% + 20% performance feeLU0417598017
RC1EUR2 5002.0% + 20% performance feeLU0417597555

Institutional share class information

SHARE CLASS CURRENCY MINIMUM INVESTMENT ANNUAL MANAGEMENT + PERF. FEE ISIN
IC1 EUR 250 000 1.5% + 20% performance fee LU0417598108
IC2 SEK 50 000 000 1.0% + 20% performance fee LU0417598793
ID1 SEK 100 000 1.5% + 20% performance fee LU0417599098
IC1 USD 300 000 1.5% + 20% performance fee LU0417598280
IC2 USD 6 000 000 1.0% + 20% performance fee LU0417598520

For more detailed information please refer to the prospectus and the fund fact sheets which can be found through our document library. There you can also find performance scenarios.


If you have any questions, please send an email to info@rhepa.com


Fund management

The fund is managed by ONE Fund Management S.A., who have commissioned Rhenman & Partners Asset Management to manage the fund’s portfolio.

Rhenman & Partners is authorized to conduct securities operations in the form of discretionary portfolio management regarding financial instruments. This means that Rhenman & Partners manages the fund’s portfolio, i.e. buys and sells securities within the framework of the fund’s investment regulations. However, we do not provide investment advice. Investors who are considering investing in the fund are strongly recommended to discuss investment questions with a professional investment advisor. For more information regarding the fund’s legal structure, please refer to the prospectus and the fund fact sheets.

EN